News | April 25, 2007

Cardiologist Launches New Heart Supplements

April 26, 2007 — Cardiologist Lee A. Surkin, M.D., FAAC, is set to launch a new line of cardiac nutritional supplements this July. He says the new Cardiac Wellness Supplements are designed to complement, not replace, standard cardiovascular disease prevention and treatment therapies.

"Simply put, I developed Cardiac Wellness Supplements out of necessity," said Dr. Surkin. "I believe in an integrative approach to the prevention and treatment of cardiovascular disease. That means traditional medical care, exercise, and basic nutrition. As my patients became more educated, they asked me for recommendations for supplements to help improve their nutrition. I wasn't able to find the right supplements to meet their needs, so I developed my own proprietary line of products that I am now bringing to a broader market."

"Supplements are a worrisome area for many physicians because in most cases there is a real lack of solid scientific data to support safety or outcome," said Dr. Surkin. "As I looked at products available in the marketplace, I found few suitable options. And of the products I was comfortable recommending, expense was almost always an obstacle. Now, with my Wellcor Products, I can comfortably recommend products that have data to support them and are cost-effective."

Dr. Surkin utilized his training in human nutrition and cardiology to develop Cardiac Wellness Supplements, focusing on ingredients that have substantial scientific data on safety, efficacy and dosage. The product line will include five products: Wellcor Defense -- Omega 3, Wellcor Energize -- Supreme Green Tea, Wellcor Guard -- Resveratrol / Quercitin, Wellcor Strength -- CoEnzyme Q10 / Hawthorn and Wellcor Control -- Alpha-Lipoic Acid / L- Carnitine.
For more information visit www.cardiacwellness.com.

Related Content

Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
Overlay Init